Group One Trading’s ARS Pharmaceuticals SPRY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1K Sell
125
-11,762
-99% -$101K ﹤0.01% 7182
2026
Q1
$95.5K Buy
11,887
+2,370
+25% +$22.7K ﹤0.01% 4778
2025
Q4
$111K Buy
9,517
+1,819
+24% +$17.7K ﹤0.01% 4922
2025
Q3
$77.4K Buy
+7,698
New +$110K ﹤0.01% 5569
2025
Q1
Sell
-10,916
Closed -$131K 8331
2024
Q4
$115K Sell
10,916
-39,575
-78% -$554K ﹤0.01% 4393
2024
Q3
$732K Buy
+50,491
New +$601K ﹤0.01% 2563
2024
Q1
Sell
-104,067
Closed -$776K 7921
2023
Q4
$570K Sell
104,067
-7,004
-6% -$30.7K ﹤0.01% 2953
2023
Q3
$420K Buy
+111,071
New +$729K ﹤0.01% 3084
2022
Q2
Sell
-200
Closed -$697 8487
2022
Q1
$1K Buy
+200
New +$871 ﹤0.01% 7875

Other funds holding SPRY

Group One Trading's SPRY Position: Q2 2026 in Review

Group One Trading reduced its ARS Pharmaceuticals (SPRY) stake by 99% in Q2 2026, selling an estimated $101K and leaving 125 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #7182.

Group One Trading first reported a position in SPRY in Q1 2022 and has held it in 9 quarters since. The position peaked at $732K in Q3 2024. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Group One Trading held 125 shares of ARS Pharmaceuticals worth $1K as of Q2 2026.
  • Group One Trading sold 11,762 ARS Pharmaceuticals shares in Q2 2026, an estimated $101K.
  • ARS Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #7182 holding.
  • Group One Trading first reported a position in ARS Pharmaceuticals in Q1 2022 and has held it in 9 quarters since.
  • Group One Trading's ARS Pharmaceuticals position peaked at $732K in Q3 2024.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.